Education
About Us
Working with TipRanks
Follow Us
RepliCel Life Sciences Inc (REPCF)
OTHER OTC:REPCF
REPCF Stock Chart & Stats
$0.01
$0.00(0.00%)
At close: 4:00 PM EST
$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.01
Previous CloseN/A
Volume18.85K
Average Volume (3M)2.62K
Market Cap
$764.24K
Enterprise ValueN/A
Total Cash (Recent Filing)$148.95K
Total Debt (Recent Filing)$1.24M
Price to Earnings (P/E)―
Beta194.14
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding73,577,805
10 Day Avg. Volume2,644
30 Day Avg. Volume2,620
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RepliCel Life Sciences News
REPCF FAQ
What was RepliCel Life Sciences Inc’s price range in the past 12 months?
RepliCel Life Sciences Inc lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
What is RepliCel Life Sciences Inc’s market cap?
RepliCel Life Sciences Inc’s market cap is $764.24K.
When is RepliCel Life Sciences Inc’s upcoming earnings report date?
RepliCel Life Sciences Inc’s upcoming earnings report date is Jun 02, 2026 which is in 161 days.
How were RepliCel Life Sciences Inc’s earnings last quarter?
RepliCel Life Sciences Inc released its earnings results on Aug 27, 2025. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is RepliCel Life Sciences Inc overvalued?
According to Wall Street analysts RepliCel Life Sciences Inc’s price is currently Overvalued.
Does RepliCel Life Sciences Inc pay dividends?
RepliCel Life Sciences Inc does not currently pay dividends.
What is RepliCel Life Sciences Inc’s EPS estimate?
RepliCel Life Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RepliCel Life Sciences Inc have?
RepliCel Life Sciences Inc has 73,577,805 shares outstanding.
What happened to RepliCel Life Sciences Inc’s price movement after its last earnings report?
RepliCel Life Sciences Inc reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of RepliCel Life Sciences Inc?
Currently, no hedge funds are holding shares in REPCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RepliCel Life Sciences Inc
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Technical Analysis
Ownership Overview
29.28%
Insiders
― Other Institutional Investors
70.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---